Drug Trial Radar · NCT06281756
Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia
Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
600
Planned (sponsor's estimate)
Start
Mar 20, 2024
Primary completion
Nov 30, 2027
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Milton S. Hershey Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Feb 28, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.
Conditions
- Insomnia
- Insomnia Chronic
- Insomnia, Primary
- Blood Pressure
- Blood Pressure, High
Interventions
Cognitive Behavioral Treatment for Insomnia (CBT-I)Behavioral
Subjects will receive therapy for 8 weeks
TrazodoneDrug
Non-remitting subjects will receive Trazodone (dosage) for 8 weeks
PlaceboOther
Non-remitting subjects will receive placebo for 8 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I)Time frame: 9 weeks
- Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT)Time frame: 9 weeks
- Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT TreatmentTime frame: 35 weeks
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
National Jewish Health
Denver, Colorado · Recruiting
Penn State University
Hershey, Pennsylvania · Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania · Recruiting
Université Laval
Québec, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.